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OBJECTIVE: The aim of this study was to evaluate and
compare the expression of metalloproteinases-1, -2, and
-9 in solid ameloblastoma and adenomatoid odontogenic
tumor.
METHODS: A total of 20 cases of solid ameloblastoma
and 10 cases of adenomatoid odontogenic tumors were
selected and immunohistochemically assessed. Metallo-
proteinases-1, -2, and -9 immunoexpression and their
distribution pattern were noted and semiquantitatively
scored. The scores obtained were statistically analyzed.
RESULTS: Matrix metalloproteinase (MMP)-1 showed a
predominant expression in both tumors and was found in
stroma and parenchyma. For MMP-2, there was a varied
expression, with 80% and 60% of immunoreactive tumor
cells in ameloblastoma and adenomatoid odontogenic
tumor respectively. Regarding stromal cells, 65% of
ameloblastomas and 80% of adenomatoid odontogenic
tumors showed positivity. There was immunoexpression
of the MMP-9 in parenchymal and stromal cells in all
cases of both tumors analyzed. A statistically significant
difference in the expression of MMP-1 in relation to the
expression of MMP-2 and -9 in ameloblastomas
(P < 0.001) was observed.
CONCLUSION: The results suggest that these metallo-
proteinases are related to growth and progression of
tumors analyzed, and particularly in ameloblastoma, its
highest aggressiveness may be, in part, a result of the
active participation of the stromal cells and their prod-
ucts, such as the MMPs studied.
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Introduction
The ameloblastoma and adenomatoid odontogenic
tumor are two representatives of benign tumors derived
from odontogenic epithelium, without the participation
of the ectomesenchyma (Barnes et al, 2005).
The solid ameloblastoma is an odontogenic neoplasm
that, although it has a benign nature, also has an
aggressive and invasive behavior and high rate of
recurrence (Neville et al, 2004; Barnes et al, 2005;
Kumamoto and Ooya, 2006). The adenomatoid odon-
togenic tumor is a slow-growing, but progressive, lesion
(Silva et al, 2004; Leon et al, 2005).
The matrix metalloproteinases (MMPs) comprise a
family of zinc-dependent endopeptidases that have the
ability to degrade the components of the extracellular
matrix (ECM), participating in physiologic events and
pathologic processes (Mott and Werb, 2004). Several
studies have emphasized the action and the importance
of MMPs in the growth of pathological processes of all
kinds. These proteases have the ability to act on the
components of the ECM, favoring the invasion and
proliferation of neoplastic cells (Souza and Line, 2002).
To better understand the interaction between tumor
cells and the ECM in ameloblastoma and adenomatoid
odontogenic tumor, this study aimed to evaluate
and compare the immunohistochemical expression
of MMPs-1, -2, and -9 in odontogenic tumors cited
by a semi-quantitative descriptive and comparative
analysis of the pattern of the expression of these metallo-
proteinases.
Materials and methods
The research received approval from the Research
Ethics Committee of the Federal University of Rio
Grande do Norte for its implementation.
The selected sample at the Laboratory of Pathologic
Anatomy of the Discipline of Oral Pathology at Federal
University of Rio Grande do Norte consisted of 20 cases
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of solid ameloblastomas and 10 cases of adenomatoid
odontogenic tumors diagnosed according to the classi-
ﬁcation of the World Health Organization (Barnes et al,
2005).
The selected material was ﬁxed in formalin at 10%
and embedded in paraﬃn. There were histologic sections
of 3 lm thick which were extended on glass slides
containing adhesive based on 3-amino-silane-propiltrie-
toxi (Signa Chemical CO, St. Louis, MO, USA). The
histologic sections were submitted to dewaxing in xylene
through two baths, the ﬁrst being at 60C for 30 min
and the second at room temperature for 20 min. The
sections were re-hydrated in string of alcohol in the
water and washed up in two passages of distilled water
for 5 min each. The blocking of endogenous peroxidase
activity was performed using hydrogen peroxide of 10
volumes. Subsequently, the sections were washed in
water and immersed twice in buﬀer solution of Tris
(hydroxymethyl) aminomethane (TRIS-HCL), pH 7.4,
for 5 min each. There was the incubation of the sections
with antibodies diluted in TRIS-HCL buﬀer solution
(Table 1) with the streptavidin–biotin complex (Dako-
Cytomation LSAB+System-HRP, Dakocytomation,
A ⁄ S, Glostrup, Denmark) during 30 min at room
temperature. It was applied the chromogenic agent
diaminobenzidine diluted in TRIS-HCL added with
hydrogen peroxide at 10 volumes in a dark room for
3 min to the revelation. The samples were counter-
stained with Mayer hematoxylin for 10 min, rinsing with
water after each step. Finally, dehydration in ethanol
and xylene clearing were carried out for assembling the
glass slides with Erv-mount.
The immunohistochemical analysis, the presence or
absence of immunohistochemical expression of MMP-1,
-2, and -9 and the pattern of distribution (focal and
diﬀuse), was veriﬁed by two examiners at diﬀerent times.
Semi-quantitative analysis of immunostained cells was
performed using the following scores (adapted from
Nagel et al, 2004): 0 (<10% of positive tumor cells),
1 (10–50% of positive tumor cells), 2 (>50% of positive
tumor cells). After obtaining the data, a descriptive
analysis of the results was carried out. In the statistical
analysis, the non-parametric Pearson’s chi-square test,
with a signiﬁcance level of 5%, was used to evaluate the
diﬀerence between the scores in each tumor. The scores
were dichotomized to reduce the dispersion of data.
Results
There was immunohistochemical expression of MMPs-
1, -2, and -9 in the parenchyma and the stroma of solid
ameloblastomas and adenomatoid odontogenic tumors,
and the MMP-1 had a predominant immunostaining in
the two tumors analyzed. The neoplastic cells in
ameloblastoma showed immunoreactivity in the cell
cytoplasm independent of being located on the periph-
ery or on the central portion of nests for all MMPs
analyzed.
In solid ameloblastomas, the MMP-1 was observed in
all examined cases in both parenchyma and stroma
(Figure 1). For the MMP-2, the expression was varied.
There was positivity in 80% of the specimens (Figure 2)
and 20% had no immunostaining in tumor cells.
Considering the stroma, 65% of cases of ameloblastoma
were positive. The immunoreactivity for MMP-9 was
evident in parenchymal and stromal cells (Figure 3) of
all specimens of ameloblastoma analyzed. The distribu-
tion of scores in ameloblastomas is presented in Table 2.
Regarding the pattern of distribution, there was a
predominance of the diﬀuse pattern for MMP-1 and -9,
while for the MMP-2, there was no predominance in the
pattern of distribution of the cells, with 50% being focal
and 50% diﬀuse. The expression of MMP-1 in tumor
cells of ameloblastomas was statistically signiﬁcant
(P < 0.001) when compared with the expression of
the MMP-2 and -9 (Table 3).
The adenomatoid odontogenic tumors showed posi-
tivity in tumor cells, regardless of their location, and
in stromal cells in all cases examined for MMP-1
(Figure 4) and -9 (Figure 5). In areas where the cell was
Table 1 Applied monoclonal antibodies and stained conditions
Clone Speciﬁcation Source Dilution Incubation time Antigen retrieval
41-1E5 MMP-1 Calbiochem 1:100 Overnight (18 h) Citrate pH 6.0 Pa
17B11 MMP-2 Novocastra 1:50 60 min EDTA pH 8.0 Pa
2C3 MMP-9 Novocastra 1:20 Overnight (18 h) Citrate pH 6.0 Pa
Figure 1 Immunoexpression of MMP-1 in neoplastic cells of amelo-
blastoma. Cytoplasm of the peripheral columnar cells and cells in the
central portion of neoplastic nests were stained in brown. Some blood
vessels, inﬁltrated immune cells, and ﬁbroblasts were also immuno-
stained (SABC, streptavidin–biotin complex, DAB chromogen, Mayer’s
hematoxylin counterstain, 400·)
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organized in a predominantly cordonal arrangement,
there has been less exuberant immunoexpression. Con-
sidering the MMP-2, there was a positive expression in
60% of cases in tumor cells and 40% were negative. The
positivity in the stroma cells was varied, with eight cases
(80%) showing positivity and two showing negativity
(20%). The percentage of immunopositive cells is shown
in Table 4. Regarding the pattern of distribution, diﬀuse
pattern was predominant for MMP-1 and -9, while for
the MMP-2, the focal pattern was predominant.
Discussion
The ameloblastoma and adenomatoid odontogenic
tumor are benign odontogenic tumors arising from
odontogenic epithelium and have diﬀerent behaviors
(Kumamoto et al, 2003; Sempere et al, 2006). The
epithelial–mesenchymal interaction is necessary for the
control and regulation of cell functions, such as prolif-
eration, diﬀerentiation, apoptosis, and migration
(Medeiros, 2001; Raitz et al, 2003; Mott and Werb,
2004).
Thematrix metalloproteinases are important proteases
that act on the structural and functional modiﬁcations of
ECM components. In physiologic conditions, the MMPs
Figure 2 Immunohistochemical staining for MMP-2 in tumor and
stromal cells of ameloblastoma. Cells from the nests and cords
arrangement of the ameloblastoma showed brown immunostaining in
the cytoplasm. In the stroma, endothelial and inﬂammatory cells also
showed immunopositivity (SABC, streptavidin–biotin complex, DAB
chromogen, Mayer’s hematoxylin counterstain, 400·)
Figure 3 MMP-9 immunoexpression in parenchymal and stromal cells
of ameloblastoma. Cells from periphery and in the central portion of
nests and cords of ameloblastoma showed brown immunostaining in
the cytoplasm (SABC, streptavidin–biotin complex, DAB chromogen,
Mayer’s hematoxylin counterstain, 400·)
Table 2 Immunoreactive score for MMPs-1, -2, and -9 in ameloblas-
toma. Natal ⁄RN, 2008
Ameloblastoma
MMP-1 MMP-2 MMP-9
n % n % n %
Score 2 18 90 3 15 3 15
Score 1 1 5 5 25 8 40
Score 0 1 5 12 60 9 45
Total 20 100 20 100 20 100
Table 3 Immunoexpression of MMPs-1, -2, and -9 in ameloblastoma.
Natal ⁄RN, 2008
Metalloproteinases
MMP-1 MMP-2 MMP-9 Total
n % n % n % n %
Absence or until 50.0% 2 10.0 17 85.0 17 85.0 36 60.0
More than 50.0% 18 90.0 3 15.0 3 15.0 24 40.0
Total 20 100.0 20 100.0 20 100.0 60 100.0
Pearson chi-square test P < 0.001.
Figure 4 Immunoexpression of MMP-1 in adenomatoid odontogenic
tumor. Whorl-shaped tumor cells nests and duct-like structures were
stained in brown in the cytoplasm (SABC, streptavidin–biotin complex,
DAB chromogen, Mayer’s hematoxylin counterstain, 200·)
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are poorly expressed by tissues, while in disease processes
there is superexpression of these due to the imbalance in
themetalloproteinases activities and their inhibitors, such
as the tissue inhibitors of matrix metalloproteinases
(TIMPs) (Pereira et al, 2005; Nagase et al, 2006; Verma
and Hansch, 2007).
Considering the odontogenic tumors, few studies have
been conducted to evaluate the expression of metallo-
proteinases in these lesions. In this study, in general, the
MMPs were expressed both in tumor cells and in the
two stromal tumors analyzed, the expression of MMP-1
being more evident.
All cases of ameloblastoma showed positivity for
MMP-1 in tumor and stromal cells. This result is
comparable with that obtained by Pinheiro et al (2004),
in which the MMP-1 was observed in tumor cells, in the
stroma, and in the interface of bone-growth ameloblas-
tomas. However, these authors found the presence of
MMP-1 only in columnar cells on the periphery of nests
of ameloblastoma, unlike that in this study, which found
tagging enzyme in cells of the periphery and the central
portion of the nests of epithelium. This result can be
explained by the presence of tenascin, which is a
substrate of MMP-1, detected in the central portion of
nests that resemble the stellate reticulum of the enamel
organ observed by Medeiros (2001).
However, Kumamoto et al (2003) found MMP-1
immunoexpression only in stromal cells of the amelobl-
astomas and not in the tumors cells. The divergent
results can be explained by the use of diﬀerent clones or,
possibly, by the temporal expression of this MMP
depending on the needs of the development of neoplasm.
The statistically signiﬁcant higher expression of
MMP-1 in relation to the MMP-2 and -9 in ameloblas-
toma, detected by Chi-square test of Pearson
(P < 0.001), shows that this metalloproteinase is one
of the major enzymes that act in the degradation of the
ECM, being essential for tumor growth, which is easily
veriﬁed and explained in ameloblastoma through its
major growth potential. The high expression of MMP-1
in ameloblastoma may be related to the largest existing
cell proliferation in this neoplasia, as has been veriﬁed
by Meer et al (2003), Santana et al (2004), and Barboza
et al (2005).
The adenomatoid odontogenic tumor, characterized
as a less aggressive lesion and with a lower proliferative
potential than ameloblastoma (Barboza et al, 2005),
also had immunostaining for the MMP-1 in parenchy-
mal and stromal cells, revealing the extreme importance
of this enzyme in the degradation of the ECM, regard-
less of the aggressiveness of the tumor.
The presence of tenascin and the collagen I, substrates
of MMP-1, in adenomatoid odontogenic tumor veriﬁed
by Medeiros (2001) may explain the positivity for
MMP-1 found in this work, both in parenchymal cells
and in stroma, conﬁrming the role of this enzyme in
tumor growth and expansion.
The expression of metalloproteinases-2 and -9 in
ameloblastomas and adenomatoid odontogenic tumors
was varied, with the MMP-9 showing higher immuno-
reactivity when compared with MMP-2. The same was
evident in works performed by Teronen et al (1995) and
Silveira et al (2007) in odontogenic cyst. These ﬁndings
may suggest a secondary role of gelatinases in the lesions
evaluated; as the MMP-1 is the main protease respon-
sible for degrading collagen I, it has a crucial role in the
degradation of ECM and tumor growth. The MMP-2
and -9 act in a combined form with the MMP-1 as they
are essential for degradation of gelatin from the break-
down of collagen type I, initiated by the MMP-1.
Poor expression of MMP-2 in parenchymal cells in
most cases examined in the two tumors was already
expected. Similar results were obtained by Pinheiro et al
(2004) that found immunostaining for the MMP-2 in
tumor cells, but only those located on the periphery of
the nests of odontogenic epithelium of ameloblastoma.
Kumamoto et al (2003) and this work showed weak
reactivity for MMP-2 in both cells of the periphery and
in cells of the central portion of the nests of odontogenic
epithelium of ameloblastomas.
The MMP-2 mainly degrades the collagen type IV,
present in the basement membrane, and other compo-
nents of ECM. We believe that the low expression of
MMP-2 is due to the need to preserve at least some of
Figure 5 Immunoexpression of MMP-9 in tumor cells of adenomatoid
odontogenic tumor. Tumor cells, rosette-like and duct-like structures,
stained in brown in the cytoplasm. Endothelial and inﬂammatory cells
were also immunostained in the cytoplasm (SABC, streptavidin–biotin
complex, DAB chromogen, Mayer’s hematoxylin counterstain, 200·)
Table 4 Immunoreactive score for MMPs-1, -2, and -9 in AOT.
Natal ⁄RN, 2008
OAT
MMP-1 MMP-2 MMP-9
n % n % n %
Score 2 10 100 0 0 6 60
Score 1 0 0 1 10 3 30
Score 0 0 0 9 90 1 15
Total 10 100 10 100 10 100
OAT, adenomatoid odontogenic tumor.
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the constituents of the basement membrane, crucial to
the process of diﬀerentiation of neoplastic cells as well as
for maintaining the structural architecture in the tumor
nests, characteristic in ameloblastoma.
The presence of ﬁbronectin, substrate of MMP-2,
observed by Medeiros (2001) in the stroma of amelobl-
astomas and adenomatoid odontogenic tumor, in the
epithelial-mesenchymal interface, as well as in the
parenchymal cells of both tumors, can justify the results
obtained in this study, in which the MMP-2 was
expressed, even if weakly, in the parenchyma and
stroma of the two tumors analyzed.
The positivity for MMP-9 observed in tumor cells of
ameloblastoma and adenomatoid odontogenic tumor in
this study highlights the involvement of metalloprotein-
ase degradation of the ECM. The MMP-9 is important,
as well as MMP-2, for the complete degradation of
collagen initiated by the MMP-1 (Teronen et al, 1995;
Cotrim et al, 2002) and consequent promotion of tumor
growth. The results found by Kumamoto et al (2003)
and Pinheiro et al (2004) in ameloblastoma are similar
in part to the results presented in this study; the
expression of MMP-9 was found only in the cells of
the periphery in the earlier studies, while in this work,
both the central portion and the periphery of nests and
cords of odontogenic epithelium showed immunoreac-
tivity for this metalloproteinase.
The low expression of MMP-2 reported during the
odontogenesis in the organ of enamel, which has as one
of its constituents the inner epithelium of the organ of
enamel composed of cells that undergo diﬀerentiation
into ameloblasts during odontogenesis, may be associ-
ated with the lowest positivity of this enzyme in
ameloblastoma, as during odontogenesis it acts in the
degradation of the basement membrane, before the start
of the formation of the enamel and dentin matrix. As
this process of diﬀerentiation in ameloblastoma is not
complete, a structural modiﬁcation of the basement
membrane through its degradation is not necessary;
therefore, large amounts of MMP-2 and -9 to degrade
the collagen IV are also not necessary.
The presence of MMP-2 and -9 in ameloblastomas
and in adenomatoid odontogenic tumor is possibly
related to cell diﬀerentiation that occurs in tumor cells.
According to Murata et al (2000), cells that form the
duct-like structures in adenomatoid odontogenic tumor
cells are diﬀerentiated in cells similar to ameloblasts, but
do not undergo the process of maturation and have the
capacity to produce molecules of ECM. Similarly, the
ameloblastomas exhibit high columnar or cubic cells of
the periphery of the nests of odontogenic epithelium,
recalling the ameloblasts, but also did not reach
the necessary maturity to the formation of enamel
(Tsujigiwa et al, 2005).
The positivity displayed by the three metalloprotein-
ases studied in stromal cells of the two tumors shows that
these enzymes are produced by ﬁbroblasts and endothe-
lial and inﬂammatory cells, such as lymphocytes, plasma
cells, macrophages, and neutrophils that are also
involved in the degradation of ECM, contributing to
the growing tumor. Similarly, the results of Kumamoto
et al (2003) and Pinheiro et al (2004) showed positivity
for the MMPs evaluated in stromal cells of ameloblas-
tomas, showing that these enzymes are probably synthe-
sized by tumor induction and in response to cytokines,
growth factors, and hormones, and are linked to tumor
progression.
Although nostatistically signiﬁcant diﬀerence was
found between the expression of MMPs in the paren-
chymal cells of ameloblastomas and of adenomatoid
odontogenic tumors, the greater aggressiveness of ame-
loblastomas may possibly be associated with the highest
amount of stromal cells in this tumor; the presence of
the metalloproteinases detected in mesenchymal cells,
conﬁrms the participation of the enzymes in the degra-
dation of the constituents of ECM, thereby promoting
tumor growth.
It should be emphasized that through immunohis-
tochemical technique, in this study as well as in the
one from Kumamoto et al (2003), it is possible to
detect the presence or absence of MMP-1, -2, and -9 in
the tumors tested, though it is not possible to
determine the enzymatic activity of these metallopro-
teinases. But in the study developed by Ikebe et al
(1999), it was observed that there is correlation
between the results of the zimography technique
performed to verify the activity of metalloproteinases
and the degree of expression displayed by immunohis-
tochemical tests.
From the obtained results, which characterized the
presence of MMP-1, -2, and -9 in the cells of the stroma
and the parenchyma of ameloblastomas and adenoma-
toid odontogenic tumors and its active participation in
the growth of those tumors, it is believed that studies
using more sensitive techniques must be carried out in
an attempt to better understand the role and inﬂuence of
these enzymes in the local behavior of the tumors
studied.
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